2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia

Annals of Hematology

Volumn 76, Issue 1, 1998, Pages 19-23

  Van Den Neste, E ^a   Martiat, P ^a   Mineur, P ^b   Delannoy, A ^c   Doyen, C ^d   Zenebergh, A ^a   Michaux, J L ^a   Ferrant, A ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Hopital St Joseph   (Belgium)

^c Hospital de Jolimont   (Belgium)

^d UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

2 CdA; Acute myeloid leukemia; Daunorubicin; Refractory leukemia

Indexed keywords

CLADRIBINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; HUMAN; INFECTION; LIVER TOXICITY; MALE; MENTAL DISEASE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CLADRIBINE; DAUNORUBICIN; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031964178     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050355     Document Type: Article

References (20)

1. Carson DA, Wasson DB, Teatle R,Yu A (1983) Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62:737-743
2. Carson DA, Seto S, Wasson DB, Carrera CJ (1986) DNA strandbreaks, NAD metabolism, and programmed cell death. Exp Cell Res 164:273-281
3. Delannoy A (1996) 2-Chloro-2′-deoxyadenosine: clinical applications in hematology. Blood Rev 10:148-166
4. Delannoy A, Martial P, Gala JL, Denevs V, Ferrant A. Bosly A, Scheiff JM, Michaux JL (1995) 2-Chlorodeoxyadenosine (2-CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 9:1130-1135
5. Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W (1996) Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87:256-264
6. Hurwitz GA, Krance R, Schell MJ, Santana VM, Brenner MK, Ribeiro R, Roberts WM, Mahmoud H, Belt J, Crom W, Shearer PD, Mirro J (1992) Current strategies for treatment of acute myeloid leukemia at St. Jude Children's Research Hospital. Leukemia 6 [Suppl 2]:39-43
7. Juliusson G, Liliemark J (1994) 2-Chlorodeoxyadenosine with and without cytosine arabinoside and idarubicin for acute myeloid and lymphoid leukemia - clinical and pharmacokinetic studies. Br J Haematol 87 [Suppl 1]:12
8. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ (1988) Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 2:403-412
9. Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E (1996) Clinical and laboratory studies of 2-chlorodeoxyadenosine ± cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10:1563-1569
10. Kristensen J, Nygren P, Liliemark J, Fridborg H, Killander A, Simonsson B, Öberg G, Larsson R (1994) Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia. Leukemia 8:1712
11. Larsson R, Fridborg H, Liliemark J, Csoka K, Kristensen J, de la Torre M, Nygren P (1994) In vitro activity of 2-chlorodeoxyadenosine in primary cultures of human haematological and solid tumors. Eur J Cancer 30A:1022-1026
12. Larson A, Mick R, Spielberger RT, O'Brien SM, Ratain MJ (1996) Dose-escalation trial of cladribine using five daily infusions in patients with advanced hematologic malignancies. J Clin Oncol 14:188-195
13. Liliemark J, Juliusson G (1995) Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1:385-390
14. Nagourney RA, Evans SS, Messencer JC, Zhuang Su Y, Weisenthal LM (1993) 2-Chlorodeoxyadenosine activity and cross-resistance patterns in primary cultures of human hematological neoplasms. Br J Cancer 67:10-14
15. Pilgram WJ, Fuller W, Amilton LDH (1972) Stereochemistry of intercalation: interaction of daunorubicin with DNA. Nature 235:17
16. Raza A, Preisler H, Lampkin B, Yousuf N, Tucker C, Peters N, White M, Kukla C, Gartside P, Siegrist C, Bismayer J, Barcos M, Bennett J, Browman G, Goldberg J, Grunwald H, Larson R, Vardiman J, Vogler R (1991) Biological significance of cell cycle kinetics in 128 standard-risk newly diagnosed patients with acute myelocytic leukaemia. BrJ Haematol 79:33-39
17. Santana VM, Mirro J, Harwood FC, Cherrie J, Schell M, Kalwinsky D, Blakley RL (1991) A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 9:416-422
18. Santana VM, Mirro J, Kearns C, Schell MJ, Crom W, Blakley RL (1992) 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10:364-370
19. Santana VM, Hurwitz GA, Blakley RL, Crom WR, Luo X, Roberts WM, Ribeiro R, Mahmoud H, Krance RA (1994) Complete hematological remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 84:1237-1242
20. Vahdat L, Wong ET, Wile MJ, Rosenblum M, Foley KM, Warrell RP (1994) Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 84:3429-3434